US Congress passes bill that reauthorises the FDA’s paediatric priority voucher pathway for five more years
For Ilya Pharma, receiving a RPDD with PRV eligibility in 2024, this is a meaningful milestone providing security of a commercially viable development for our lead program developing ILP100-Topical as a limb-saving treatment in children with the rare disease SAVI.
Link to news reporting of the event: https://everylifefoundation.org/congress-passes-five-year-reauthorization-of-rare-pediatric-disease-prv-program/